Oryzon reduces losses by 7.7% in the year of the pandemic

The company has recorded a negative result of 3.4 million euros at the end of the 2020 financial year.

The biopharmaceutical company Oryzon has presented the results corresponding to the previous financial year. a year in which has reduced its losses by 7.7%, to -3.4 million euros (compared to -3.68 million euros in 2019).

This has been announced this Monday to the National Securities Market Commission (CNMV). In the note, the company explains that the negative result includes operating expenses research and development for 1.6 million euros recognized directly against losses.

These include the costs of a Phase II clinical trial with vafidemstat in seriously ill patients with Covid-19.

Likewise, Oryzon has recognized income of 1.3 million euros corresponding to the monetization of tax deductions for R&D, compared to 0.8 million in the same period of 2019, which represents an increase of 50.6%.

For his part, the heritagegrandchild of 75.9 million euros increases by 14.8 million with respect to the amount of the 2019 financial year, which was 61.1 million.